Mr Leedman has 15 years experience in the biotechnology industry. Mr Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Limited to then form ResApp Health Limited where Mr Leedman was the executive director of corporate affairs. ResApp Health Limited was acquired by Pfizer (Aust) Limited in 2022. Mr Leedman is a public company director having formerly been the chairman of Neurotech International Limited, Nutritional Growth Solutions Limited, Neuroscientific Biopharmaceuticals Limited and was a director of Alcidion Corporation Limited, Oncosil Medical Limited and Respiri Limited. Prior to ResApp, Mr Leedman co-founded OncoSil Medical Limited and Biolife Science (QLD) Limited (to be later renamed to Imugene Limited). Mr Leedman previously served for ten years as vice president, investor relations for pSivida Corp. Limited, which was listed on the ASX, Frankfurt and NASDAQ. Mr Leedman was formerly the WA chairman of AusBiotech, the association of biotechnology companies in Australia.
